RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
SMFAX
Price
$30.28
Change
-$0.11 (-0.36%)
Updated
Sep 20 closing price
Ad is loading...

RPTIX vs SMFAX

Header iconRPTIX vs SMFAX Comparison
Open Charts RPTIX vs SMFAXBanner chart's image
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
American Beacon Stephens Mid-Cap Gr A
Price$30.28
Change-$0.11 (-0.36%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RPTIX vs SMFAX Comparison Chart
Loading...
VS
RPTIX vs. SMFAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a StrongBuy and SMFAX is a Buy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. SMFAX (771M). RPTIX pays higher dividends than SMFAX: RPTIX (0.18) vs SMFAX (0.00). RPTIX was incepted earlier than SMFAX: RPTIX (9 years) vs SMFAX (13 years). RPTIX is a more actively managed with annual turnover of: 21.70 vs. SMFAX (16.00). SMFAX has a lower initial minimum investment than RPTIX: SMFAX (2500) vs RPTIX (500000). SMFAX annual gain was more profitable for investors over the last year : 23.79 vs. RPTIX (14.81). SMFAX return over 5 years is better than : 38.84 vs. RPTIX (15.09).
RPTIXSMFAXRPTIX / SMFAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years13 years-
Gain YTD9.1278.298110%
Front LoadN/AN/A-
Min. Initial Investment500000250020,000%
Min. Initial Investment IRAN/AN/A-
Net Assets31.4B771M4,073%
Annual Yield % from dividends0.180.00-
Returns for 1 year14.8123.7962%
Returns for 3 years-13.57-9.72140%
Returns for 5 years15.0938.8439%
Returns for 10 yearsN/A70.44-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp